NeilDavidPalmisianoMDMS
Oncology • New Brunswick, NJHematologic Oncology
Associate Professor of Medical Oncology
Dr. Palmisiano is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
195 Little Albany St
New Brunswick, NJ 08901Phone+1 732-235-2465- Is this information wrong?
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 2011 - 2014- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2008 - 2011
Lewis Katz School of Medicine at Temple UniversityClass of 2008
Certifications & Licensure
NJ State Medical License 2018 - 2025
PA State Medical License 2008 - 2024
DE State Medical License 2018 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Start of enrollment: 2013 Jul 08
- Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2016 Mar 01
- Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Start of enrollment: 2018 Aug 13
- Join now to see all
Publications & Presentations
PubMed
- Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: resul...Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M Shallis, Sacchi de Camargo Correia Guilherme, Aaron D Goldberg, Antoine N Saliba, Anand Patel, Jan P Bewersdorf, Adam S ...> ;Blood Cancer Journal. 2024 Feb 20
- PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.Rodriguez, C., Kang, H., Babbar, N., Sun, W., Ferrarotto, R., Swiecicki, P., Zandberg, D., Baiocchi, R., Wesolowski, R., McKean, M., Monga, V., Nath, R., Palmisiano, N...> ;Oral Oncology. 2024 Feb 1
- Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.Abid, M. B., Hemant S Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V Michelis, Taiga Nishihori, Mrinal Pat...> ;Blood Advances. 2023 Nov 28
- Join now to see all
Abstracts/Posters
- Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid MalignanciesNeil Palmisiano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid LeukemiaNeil Palmisiano, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Authored Content
- IDH Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy at SOHO 2021September 2021
Press Mentions
Neil Palmisiano, MD, Appointed as Deputy Director of Phase 1 Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute of New JerseyOctober 3rd, 2022- ASH 2023: Tailoring Treatment in AMLDecember 22nd, 2023
Hospital Affiliations
- Cancer Institute of New JerseyNew Brunswick, New Jersey
Robert Wood Johnson University HospitalNew Brunswick, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
